Ro 13-9904, a new parenteral cephalosporin, was found to have high in vitro activity against Enterobacteriaceae and other gram-negative bacteria, including various isolates resistant to cefuroxime, cefamandole, cefoxitin, and cefazolin. It showed promising activity against Pseudomonas aeruginosa. Although inhibitory against Staphylococcus aureus at concentrations readily achievable in plasma, it was less potent against this pathogen than cefamandole, cefazolin, or cefuroxime.
Since the development of cephalothin and cephaloridine, the first cephalosporins on the market, the antibacterial potency of this attractive class of antibiotics has undergone profound improvement over the years. The newest semisynthetic cephalosporins, including cefotaxime (5), ceftizoximne (6) , SCE-1365 (14) , cefoperazone (9) , and the 1-oxacephem derivative moxalactam (6059S, LY127935) (11) , have outstanding activity against many pathogens previously considered to be resistant to cephalosporins.
Unlike their antibacterial properties, the pharnacokinetic features of these new antibiotics do not appear to differ substantially from those of older compounds. Thus, plasma halflives are reported to be relatively short, ranging from 1.2 to 2.4 h in humans (2, 8, 16 ; M. Nakashima, H. Hashimoto, and K. Suzuki, Progr. Abstr. 11th Int. Congr. of Chemother. and 19th Intersci. Conf. Antimicrob. Agents Chemother. Boston, Mass., abstr. no. 555, 1979) . The ureidopenicillins, another class of highly active fi-lactam compounds, are characterized by similar pharmacokinetic behavior (7, 21) . To maintain drug concentrations effective in the treatment of most human infections, these antibiotics have to be administered several times a day. Cephalosporins, such as SK&F 75073 (1) and SK&F 80303 (22) , which have longer half-lives than other ,Blactam compounds, are not equivalent to the aforementioned new cephalosporins in either breadth or intensity of antibacterial activity.
There is a real place for a compound which combines excellent antibacterial potency with prolonged therapeutic efficacy. The pharmacokinetic behavior of cephalosporins is assumed to depend largely on the nature of the substituent at position 3 of the nucleus (12) . We report here on the in vitro and in vivo properties of a new cephalosporin, designated Ro 13-9904 ( Fig. 1 ), which has a 3-substituent hitherto not used in cephalosporin research (17) . This compound belongs to the class of 7-{2-(2-amino-4-thiazolyl)-2-[(Z)-methoxyimino]acetamido} cephalosporins, members of which are known to be highly effective but without a prolonged action in mammals (8; 19th ICAAC, abstr. no. 555). As described below, Bacterial strains. Standard strains from our culwre collection as well as clinical isolates obtained from several hospitals in Switzerland were used in this study.
In vitro susceptibility testing. The minimum inhibitory concentrations (MICs) were determined by the agar dilution method with diagnostic sensitivity test (DST) agar (Oxoid Ltd., London, England) unless otherwise specified. The antibiotics were incorporated into the agar in twofold serial dilutions. The inoculum was prepared by diluting overnight cultures to a cell concentration of 107 colony-forming units (CFU) per ml in broth. The surface of the agar was inoculated with the aid of a multipoint inoculator yielding approxiimately 104 CFU per spot. For testing streptococci, the DST agar was supplemented with 7.5% human blood. MICs against strains of Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae were determined by using chocolate DST agar. Susceptibility of anaerobes was assayed on Wilkins-Chalgren agar (23) . After 20 h of incubation at 370C, the MICs were recorded as the lowest concentrations which prevented bacterial growth.
Minimum bactericidal concentrations (MBCs) were determined by broth dilution. Overnight cultures of the strains examined were appropriately diluted and then added to 2-ml samples of Mueller-Hinton broth containing graded concentrations of Ro 13-9904. The size of inoculum ranged from 5 x 104 to 5 x 107 CFU/ ml. After incubation at 37°C for 18 h, a volume of 0.02 ml from each tube was subcultured on DST agar. The lowest concentration showing no visible growth in the tubes was taken as the MIC, and that preventing bacterial growth on the subculture plate was recorded as the MBC.
Assay of ,-lactamase. Strains used for the isolation of,-lactamases were cultured in tryptic soy broth (Difco Laboratories, Detroit, Mich.). Ampicillin at a concentration of 100,ug/ml was added in the late log phase to those strains in which ,i-lactamase was seen to be inducible. Cells harvested by centrifugation were suspended in 10 Although cefotaxime and Ro 13-9904 showed almost equivalent activity against many species, Ro 13-9904 was more active than cefotaxime against isolates of Proteus mirabilis, N. gonorrhoeae, N. meningitidis, and H. influenzae.
There were less pronounced differences between the activities of Ro 13-9904, cefotaxime, and the other compounds against gram-positive bacteria. Except for cefoxitin, Ro 13-9904 was less active against S. aureus than the other cephalosporins; however, the MICs of Ro 13-9904 were well below the plasma concentrations achievable in humans (K. Stoeckel, P. McNamara, R. Brandt, H. Plozza-Nottebrock, and W.H. Ziegler, manuscript in preparation).
Isolates of S. pyogenes were consistently susceptible to all the compounds examined, especially to cefotaxime, Ro 13-9904, cefuroxime, and cefamandole, whereas those of S. faecalis were uniformly resistant. Against B. fragilis, cefoxitin was more active than the other cephalosporins, including Ro 13-9904 and cefotaxime.
Effect of inoculum size on MIC and MBC. The influence of inoculum size on both MICs and MBCs of Ro 13-9904 against isolates of a number of different bacterial species is illustrated in Table 2 . For most strains. the MBC was equal to or only twice the MIC at inocula less than 5 x 107 CFU/ml. A pronounced difference between MICs and MBCs was observed with one strain of P. aeruginosa, for which the MBCs exceeded the MICs by a factor of 4 with inocula of 5 x 104 and 5 x 105 CFU/ml and by a factor of 32 with an inoculum of 5 x 106 CFU/ml. The effect of the inoculum size on the activity of Ro 13-9904 depended on the strain examined. Whereas there was at most a 4-fold rise in MIC as the inocula of Escherichia coli, Klebsiella pneumoniae, E. cloacae, and S. aureus were increased from 5 x 104 to 5 x 107 CFU/ml, there was a 16-to 500-fold increase in MIC for S. marcescens, P. vulgaris, and P. aeruginosa when their inocula were increased to 5 x 107 CFU/ml.
Effect of plasma and growth medium on MIC. The effect of human plasma on the in vitro activity of Ro 13-9904 was investigated in Mueller-Hinton broth on one strain each of S. aureus, E. coli, K. pneumoniae, and P. aeruginosa. In the presence of 50% human plasma, this antibiotic had but from one-half to one-sixth the activity that it had in unsupplemented broth. This decrease can be explained by the high binding of Ro 13-9904 to human plasna proteins, since at drug concentrations of up to 100 ,ug/ml, the free fraction of the compound is less than 10% (K. Stoeckel et al., manuscript in preparation).
The influence of the growth medium on the activity of Ro 13-9904 was examined by performing comparative MIC determinations on Mueller-Hinton agar, antibiotic medium no. 1, nutrient agar (all Difco), and DST agar (Oxoid). Variations in MICs were generally within a single dilution step for representative isolates of S. aureus, E. coli, S. marcescens, P. mirabilis, and P. vulgaris, but were greater for a strain of P. aeruginosa (Table 3 In addition to the strains listed in Table 4 , filactamases from nine P. aeruginosa strains did not hydrolyze Ro 13-9904. Although not a substrate, Ro 13-9904 proved to be a potent inhibitor of several f)-lactamases. (4, 10, 15) . This is in keeping with the discrepancy between antibacterial activity and /?-lactamase stability of Ro 13-9904 observed with P. vulgaris 1028 and E. cloacae 908. In the case of E. cloacae 908, factors unconnected with the action of,-lactamases appear to be involved in determining resistance to Ro 13- 
9904.
Our in vivo data on Ro 13-9904 support the contention that the pharmacokinetic properties of aminothiazole cephalosporins depend, to a great extent, on the nature of the substituent at position 3 of the nucleus. Thus, Ro showed high efficacy when given as a single dose 2 h before challenge, suggesting that active concentrations were maintained in the blood of treated animals for a prolonged period. Cefotaxime and SCE-1365, the structures of which are identical to that of Ro 13-9904 except for the substituent at position 3, showed little protective activity when administered in the same dosage schedule.
Sustained high plasma concentrations after injection of Ro 13-9904 have been demonstrated in rats (17) . This property is not confined to animals, for the mean elimination half-life of Ro 13-9904 was 8 h when this compound was administered to volunteers (K. Stoeckel et al., manuscript in preparation).
On the basis of the encouraging results obtained in these and other experimental studies, clinical trials have been initiated. 
